medRxiv preprint doi: https://doi.org/10.1101/2020.04.10.20061358; this version posted April 14, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

Sato et al.

Neuropsychiatric adverse events of chloroquine: A real-world pharmacovigilance study
using the FAERS database

Kenichiro Sato1, Tatsuo Mano1, Atsushi Iwata1,2 *, and Tatsushi Toda1

1

Department of Neurology, Graduate School of Medicine, University of Tokyo

2

Department of Neurology, Tokyo Metropolitan Geriatric Medical Center Hospital

*Correspondence: Dr. Atsushi Iwata
Department of Neurology, Tokyo Metropolitan Geriatric Medical Center Hospital
35-2 Sakaecho Itabashi-ku, Tokyo 173-0015
Phone: 81-3-3964-1141
FAX: 81-3-3964-2963
E-mail: iwata@m.u-tokyo.ac.jp

Running title: Neuropsychiatric adverse events of chloroquine

1
NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

medRxiv preprint doi: https://doi.org/10.1101/2020.04.10.20061358; this version posted April 14, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

Sato et al.

Abstract
Objectives: As of the early April 2020, the antimalarial drug, chloroquine, has been approved as an
emergency treatment for the coronavirus disease 2019 (COVID-19) in the United States and in Europe.
Although infrequent, neuropsychiatric symptoms have been reported in patients who received
chloroquine for the treatment of malaria or autoimmune diseases. In this study, we investigated these
adverse events (AEs) using a large self-reporting database.
Materials and Methods: We conducted a disproportionality analysis for the detection of
neuropsychiatric AE signals associated with the use of chloroquine (or hydroxychloroquine), reported to
FAERS database between the fourth quarter of 2012 and the fourth quarter of 2019. Adjusted reporting
odds ratio (ROR) for the development of each of the neuropsychiatric AEs following the use of
chloroquine was calculated using a multilevel model.
Results: We included 2,389,474 AE cases, among which 520 cases developed neuropsychiatric AE
following the use of chloroquine. Exposure to chloroquine was associated with a statistically significant
high reporting of amnesia, delirium, hallucinations, depression, and loss of consciousness, (lower 95%
confidence interval of the adjusted ROR > 1), although the degree of increase in their ROR was limited.
There was no statistically significant high reporting of any other neuropsychiatric AE, including suicide,
psychosis, confusion, and agitation.

2

medRxiv preprint doi: https://doi.org/10.1101/2020.04.10.20061358; this version posted April 14, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

Sato et al.

Conclusion: Current pharmacovigilance study results did not suggest any potential link between the use
of chloroquine and an increased risk of suicide, psychosis, confusion, and agitation, which would be
informative during the emergency use of chloroquine for the treatment of COVID-19.

Keywords: COVID-19; chloroquine; adverse events; pharmacovigilance; FAERS

Ôºõreal-world data.

3

medRxiv preprint doi: https://doi.org/10.1101/2020.04.10.20061358; this version posted April 14, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

Sato et al.

Introduction
The coronavirus disease 2019 (COVID-19) outbreak is a global emergency situation [1], for which the
development of drugs and vaccines has been intensively investigated worldwide. In April 2020, the US
Food and Drug Administration (FDA) [2] and the European Medicines Agency (EMA) [3] have
approved the use of chloroquine and hydroxychloroquine for an emergency treatment of COVID-19,
based on their potential effectiveness in this setting [4, 5]

.

While chloroquine has a long history in the treatment of malaria and autoimmune diseases, its
safety and efficacy in the treatment of COVID-19 remain unknown [5]. In the treatment of malaria and
autoimmune diseases, chloroquine can cause numerous side effects such as nausea, headache, pruritus,
worsening of psoriasis, retinopathy, and cardiac dysfunction. While neuropsychiatric symptoms such as
seizure, coma, and psychosis, were also reported in patients who received chloroquine [6, 7], it is still
unknown which neuropsychiatric symptoms are directly associated with the use of chloroquine, partly
because of their relatively low frequency [8]. Understanding in advance the types of neuropsychiatric
symptoms that may occur in patients treated with chloroquine, may be useful, particularly in patients
with COVID-19 in intensive care units, where rapid clinical judgement is required.
In the current study, we investigated the link between the use of chloroquine and the occurrence
of neuropsychiatric symptoms, using the FDA Adverse Event Reporting System (FAERS) database that
is provided by the FDA [9]. Since this database contains a very large number of case reports of drug
4

medRxiv preprint doi: https://doi.org/10.1101/2020.04.10.20061358; this version posted April 14, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

Sato et al.

AEs, it is widely used in identifying potential link between drugs and AEs during post-marketing
surveillance of drug safety, [10], despite the risk of bias that is associated with its self-reported data [11].

5

medRxiv preprint doi: https://doi.org/10.1101/2020.04.10.20061358; this version posted April 14, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

Sato et al.

Methods
Data acquisition and preprocessing
This was a retrospective pharmacovigilance study that used the FAERS database. This database contains
more than 9 million global case reports of potential adverse events of drugs. On April 1, 2020, we
downloaded from the FDA‚Äôs website (https://www.fda.gov) patient data that were reported between the
fourth quarter of 2012 and the fourth quarter of 2019. The FAERS database contains data tables named
‚ÄòDEMO‚Äô, ‚ÄòDRUG‚Äô, ‚ÄòREAC‚Äô, ‚ÄòOUTC‚Äô, ‚ÄòRPSR‚Äô, ‚ÄòTHER‚Äô, and ‚ÄòINDI‚Äô, of which we mainly used the
following 3 tables: 1) ‚ÄòDEMO‚Äô, which provides the case ID, sex, age, year of event occurrence, country
of event occurrence, and the reporter‚Äôs type of occupation (e.g., medical doctor, pharmacist, lawyer,
consumer); 2) ‚ÄòREAC‚Äô, which contains all adverse events that are potentially caused by the drug used by
each patient, and 3) ‚ÄòDRUG‚Äô, which includes the name, dose, indication, and date of administration and
discontinuation of each drug that is possibly associated with that AE. In the ‚ÄòDRUG‚Äô table, the causality
assessment of the relationship between each drug and its reported AE is classified by the reporter as
‚Äòprimary suspected‚Äô, ‚Äòsecondary suspected‚Äô, ‚Äòconcomitant‚Äô, or ‚Äòinteracting‚Äô. In our analysis, we included
only reports that were classified as ‚Äòprimary suspected‚Äô and ‚Äòsecondary suspected‚Äô, to reduce the risk of
false positive association in deriving our conclusions. In addition, we included only reports that were
reported from medical doctor, pharmacist, or other medical staffs, and not from lawyers or consumers.

6

medRxiv preprint doi: https://doi.org/10.1101/2020.04.10.20061358; this version posted April 14, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

Sato et al.

Duplicate reports were excluded such that only the latest version of the report that was obtained from the
same case ID was retained.

Database search
In the FAERS database, the AEs are mainly identified by their Preferred Terms (PTs), as determined by
the Medical Dictionary for Regulatory Activities (MedDRA). To search for cases that were associated
with chloroquine (including hydroxychloroquine) or mefloquine treatment and presented with any of the
AEs of interest, we used the following neurological or psychiatric AE terms, as summarized in
Supplemental Table 1: ‚ÄòSeizure‚Äô (PT: 10039906), ‚ÄòLoss of consciousness‚Äô (PT: 10024855), ‚ÄòConfusional
state‚Äô (PT: 10010305), ‚ÄòComa‚Äô (PT: 10010071), ‚ÄòStupor‚Äô (PT: 10042264), ‚ÄòSomnolence‚Äô (PT:
10041349), ‚ÄòSedation‚Äô (PT: 10039897), ‚ÄòLethargy‚Äô (PT: 10024264), ‚ÄòDelirium‚Äô (PT: 10012218),
‚ÄòDisorientation‚Äô (PT: 10013395), ‚ÄòHallucination‚Äô (PT: 10019063), ‚ÄòDelusion‚Äô (PT: 10012239), ‚ÄòParanoia‚Äô
(PT: 10033864), ‚ÄòAnxiety‚Äô (PT: 10002855), ‚ÄòAnger‚Äô (PT: 10002368), ‚ÄòAggression‚Äô (PT: 10001488),
‚ÄòNervousness‚Äô (PT: 10029216), ‚ÄòIrritability‚Äô (PT: 10022998), ‚ÄòMood altered‚Äô (PT: 10027940),
‚ÄòAbnormal behavior‚Äô (PT: 10061422), and ‚ÄòRestlessness‚Äô (PT: 10038743). In addition, several AE terms
were similar, and were therefore treated collectively, based on a single AE category, as follows:
‚ÄòDizziness‚Äô (PT: 10013573) and ‚ÄòDizziness postural‚Äô (10013578) were treated as dizziness, ‚ÄòAmnesia‚Äô
(PT: 10001949) and ‚ÄòAnterograde amnesia‚Äô (PT: 10002711) were treated as amnesia, ‚ÄòAltered state of
7

medRxiv preprint doi: https://doi.org/10.1101/2020.04.10.20061358; this version posted April 14, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

Sato et al.

consciousness‚Äô (PT: 10001854) and ‚ÄòMental status changes‚Äô (PT: 10048294) were treated as altered
mental status (AMS), ‚ÄòAcute psychosis‚Äô (PT: 10001022) and ‚ÄòPsychotic disorder‚Äô (PT: 10061290) were
treated as psychosis, ‚ÄòAgitation‚Äô (PT: 10001497) and ‚ÄòPsychomotor hyperactivity‚Äô (PT: 10037211) were
treated as agitation, ‚ÄòDepressed mood‚Äô (PT: 10012374) and ‚ÄòDepression‚Äô (PT: 10012378) were treated as
depression, ‚ÄòPanic attack‚Äô (PT: 10033664) and ‚ÄòPanic reaction‚Äô (PT: 10033670) were treated as panic,
‚ÄòNightmare‚Äô (10029412) and ‚ÄòAbnormal dreams‚Äô (10000125) were treated as nightmare, and ‚ÄòSuicidal
ideation‚Äô (PT: 10042458), ‚ÄòCompleted suicide‚Äô (PT: 10010144), ‚ÄòSuicide attempt‚Äô (PT: 10042464), and
‚ÄòSuspected suicide‚Äô (PT: 10082458) were treated suicide.
We included mefloquine as one of our drugs of interest because it is an antimalarial drug that is
known to cause neuropsychiatric AEs [12]. We classified each case report based on the following
binomial factors: ‚Äòwith‚Äô or ‚Äòwithout‚Äô exposure to the drugs of interest, and ‚Äòwith‚Äô or ‚Äôwithout‚Äô the
development of each of the AEs of interest, irrespective of the timing of drug administration or the time
of AE development.

Statistical analyses
All data handling and statistical analyses were performed using R software (version 3.5.1). For each
included drug (chloroquine or mefloquine), we calculated the reporting odds ratio (ROR), to assess the
potential drug-AE links for chloroquine (or mefloquine) and the reported neuropsychiatric symptoms.
8

medRxiv preprint doi: https://doi.org/10.1101/2020.04.10.20061358; this version posted April 14, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

Sato et al.

The crude ROR was calculated by a 2 √ó 2 contingency table as described previously [13-15], where all
the reports were classified by two factors for each AE term and for each drug, as described above. When
the lower limit of the 95% confidential interval (CI) for the adjusted ROR was > 1, the AE was
considered to be significantly highly reported following the use of the drug of interest, compared with
the report of the same AE following the use of all other drugs.
In calculating ROR, we used a multilevel model, to adjust for covariates in a hierarchical design,
as described previously [16, 17]: we incorporated into the model the year of AE occurrence and the
country of AE occurrence as random effect terms, to reduce bias in the data. Accordingly, the adjusted
ROR was calculated by the following formula [16]:

  1| , 
    0| ,       
where,



‡Øú

‡Øú

‡Øú

‡Øú

‡Øú

‡Øú

‡Øú

‡Øç
‡Øú

‡Øç
‡Øú

is binomial status for with/without AE of interest in each case ,

effect parameters,
parameters, and

‡Øú

‡Øú

is the covariates matrix for fixed effect,





is the vector of fixed

is the vector of random effect

is the covariates matrix of random effect. Covariates to measure fixed effect include

age, sex, binomial exposure to chloroquine (0 if not used, and 1 if used), and binomial exposure to
mefloquine (0 if not used, and 1 if used). And covariates to measure random effect (as random
intercepts) are the calendar year between 1990 and 2019, and the regional code of the country (e.g., the
United States, Great Britain, Canada, Germany, Japan). We used the R package lme4 [18] to perform the
above multilevel model analysis.
9

medRxiv preprint doi: https://doi.org/10.1101/2020.04.10.20061358; this version posted April 14, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

Sato et al.

Ethics
This study was approved by the University of Tokyo Graduate School of Medicine institutional ethics
committee [ID: 11754-(1)]. An informed consent was not required for this type of study. The work was
conducted in accordance with the ethical standards laid out in the Declaration of Helsinki, 1964.

10

medRxiv preprint doi: https://doi.org/10.1101/2020.04.10.20061358; this version posted April 14, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

Sato et al.

Results
In total, our analysis included 2,389,474 unique case reports. There were 4,336 case reports with
exposure to chloroquine, of which 520 (12.0%) reported neuropsychiatric AEs. The number of reported
cases with exposure to mefloquine was only 67, of which 28 (41.8%) included neuropsychiatric AEs.
Patients treated with chloroquine were predominantly female (3452 females (81.9%) versus 762 males)
and the median age of the patients was 56.0 (IQR: 45.0‚Äì65.0).
Patients treated with mefloquine were predominantly male (40 males (62.5%) versus 24 females) with a
median age of 40.0 (IQR: 27.0‚Äì72.0). There were no cases of concomitant exposure to chloroquine and
mefloquine.
Figure 1 provides forest plots of the adjusted RORs and the their 95% CI for each
neuropsychiatric AE following the use of chloroquine (Figure 1A) or mefloquine (Figure 1B). In the
case of chloroquine-associated AEs (Figure 1A), only 5 AE types, including loss of consciousness
(LOC) (adjusted ROR, 1.31; 95% CI, 1.03‚Äì1.66), amnesia (adjusted ROR, 1.30; 95% CI, 1.02‚Äì1.66),
delirium (adjusted ROR, 1.58; 95% CI, 1.06‚Äì2.34), hallucination (adjusted ROR, 2.12; 95% CI,
1.54‚Äì2.92), and depression (adjusted ROR, 1.47; 95% CI, 1.22‚Äì1.77) had significantly high reporting
(lower limit of the 95% CI > 1). As for mefloquine (Figure 1B), all of the neuropsychiatric AEs, except
for somnolence, showed high reporting, with adjusted ROR values higher that 2 in almost all cases.

11

medRxiv preprint doi: https://doi.org/10.1101/2020.04.10.20061358; this version posted April 14, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

Sato et al.

Discussion
In this study, we investigated reports of neuropsychiatric AEs that were developed following exposure
to chloroquine as a treatment for malaria or autoimmune diseases. The major strength of our study is that
it was based on a database that includes global real-world data from a very large number of patients. Our
results showed a statistically significant association (albeit marginal) between the use of chloroquine and
the reporting of LOC, amnesia, delirium, hallucination, and depression, however, there was no
statistically significant association between the use of chloroquine and the reporting of suicide,
psychosis, confusion, or agitation, suggesting that there is no link between the use of chloroquine and
the increased risk of these AEs. Conversely, mefloquine showed to be associated with statistically
significant high reporting of most of the neuropsychiatric AEs, which is consistent with some of the
earlier literature reports [12, 19].
Our study has some limitations, resulting from the use of self-reported data [11], and it
therefore includes some bias that cannot be eliminated. First, this setting may be associated with a
reporting bias, that is, over- or under-reporting of neuropsychiatric AEs following the use of chloroquine.
Second, due to the absence of denominators, we were not able to discuss the incidence rate of each
neuropsychiatric AE. Third, in our multivariate adjustment, we did not consider the use of concomitant
medications or the medical history of the patients, both of which could have potentially contributed to
the development or to the worsening of some neuropsychiatric symptoms. Fourth, while suicide was
12

medRxiv preprint doi: https://doi.org/10.1101/2020.04.10.20061358; this version posted April 14, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

Sato et al.

included as one of the AEs in our analysis, it is possible that some of the suicide cases represent suicide
by chloroquine overdose, which is known to be cardiotoxic, and not an AE of chloroquine [6]. Fifth, we
have not included the timing or the total dose of chloroquine and mefloquine in the analysis. Lastly, it is
possible that our final dataset included duplicated cases that should have been excluded.
To conclude, the current pharmacovigilance study, using the FAERS database, did not suggest a
potential link between the use of chloroquine and an increased risk of suicide or psychosis. These results
provide information that can be essential when the use of chloroquine is considered for the treatment of
patients with COVID-19. Since this study was based on a self-reporting database that inevitably contains
several biases, cohort studies are needed, to validate these results and to confirm the neuropsychiatric
safety of chloroquine.

13

medRxiv preprint doi: https://doi.org/10.1101/2020.04.10.20061358; this version posted April 14, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

Sato et al.

Acknowledgments
This study was performed using the FDA Adverse Event Reporting System (FAERS) database that was
provided by the FDA. The information, results, or interpretation of the current study do not represent
any opinion of the FDA. This study received no funding.

Conflicts of interest
The authors have no potential conflict of interest to disclose, specifically with regards to Sanofi S.A.,
which sells Plaquenil (Hydroxychloroquine).

14

medRxiv preprint doi: https://doi.org/10.1101/2020.04.10.20061358; this version posted April 14, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

Sato et al.

References
[1] Verity R, Okell LC, Dorigatti I, et al. Estimates of the severity of coronavirus disease 2019: a
model-based analysis. Lancet Infect Dis. 2020 Mar 30. pii: S1473-3099(20)30243-7.
[2] FDA. Coronavirus (COVID-19) Update: Daily Roundup March 30, 2020.
(https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-m
arch-30-2020): Accessed on April 6th, 2020.
[3] EMA. COVID-19: chloroquine and hydroxychloroquine only to be used in clinical trials or
emergency use programmes. EMA/170590/2020.
(https://www.ema.europa.eu/en/documents/press-release/covid-19-chloroquine-hydroxychloroquine-onl
y-be-used-clinical-trials-emergency-use-programmes_en.pdf): Accessed on April 6th, 2020.
[4] Gao J, Tian Z, Yang X. Breakthrough: Chloroquine phosphate has shown apparent efficacy in
treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends. 2020 Mar
16;14(1):72-73.
[5] Cortegiani A, Ingoglia G, Ippolito M, Giarratano A, Einav S. A systematic review on the efficacy
and safety of chloroquine for the treatment of COVID-19. J Crit Care. 2020 Mar 10. pii:
S0883-9441(20)30390-7.
[6] AlKadi HO. Antimalarial drug toxicity: a review. Chemotherapy. 2007;53(6):385-91.

15

medRxiv preprint doi: https://doi.org/10.1101/2020.04.10.20061358; this version posted April 14, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

Sato et al.

[7] Anna Bogaczewicz, Tomasz Sob√≥w. Psychiatric adverse effects of chloroquine. Psychiatr Psychol
Klin 2017, 17 (2), p.111‚Äì114. (DOI: 10.15557/PiPK.2017.0012)
[8] Taylor WR, White NJ. Drug Saf. 2004;27(1):25-61. Antimalarial drug toxicity: a review.
[9] U.S. Food & Drug Administration. (https://www.fda.gov): Accessed on April 6th, 2020
[10] Yokoyama S, Ieda S, Nagano M, et al. Association between oral anticoagulants and osteoporosis:
Real-world data mining using a multi-methodological approach. Int J Med Sci. 2020 Feb
4;17(4):471-479.
[11] Michel C, Scosyrev E, Petrin M, Schmouder R. Can Disproportionality Analysis of Post-marketing
Case Reports be Used for Comparison of Drug Safety Profiles? Clin Drug Investig. 2017
May;37(5):415-422.
[12] Nevin RL, Byrd AM. Neuropsychiatric Adverse Reactions to Mefloquine: a Systematic
Comparison of Prescribing and Patient Safety Guidance in the US, UK, Ireland, Australia, New Zealand,
and Canada. Neurol Ther. 2016 Jun;5(1):69-83.
[13] Van Puijenbroek EP, Egberts AC, Meyboom RH, Leufkens HG. Signalling possible drug-drug
interactions in a spontaneous reporting system: delay of withdrawal bleeding during concomitant use of
oral contraceptives and itraconazole. Br J Clin Pharmacol. 1999 Jun;47(6):689-93.
[14] Rothman KJ, Lanes S, Sacks ST. The reporting odds ratio and its advantages over the proportional
reporting ratio. Pharmacoepidemiol Drug Saf. 2004 Aug;13(8):519-23.
16

medRxiv preprint doi: https://doi.org/10.1101/2020.04.10.20061358; this version posted April 14, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

Sato et al.

[15] Sato K, Mano T, Iwata A, Toda T. Neurological and related adverse events in immune checkpoint
inhibitors: a pharmacovigilance study from the Japanese Adverse Drug Event Report database. J
Neurooncol. 2019 Oct;145(1):1-9.
[16] Larsen K, Petersen JH, Budtz-J√∏rgensen E, Endahl L. Interpreting parameters in the logistic
regression model with random effects. Biometrics. 2000 Sep;56(3):909-14.
[17] Casals M, Girabent-Farr√©s M, Carrasco JL. Methodological quality and reporting of generalized
linear mixed models in clinical medicine (2000-2012): a systematic review. PLoS One. 2014 Nov
18;9(11):e112653.
[18] Douglas Bates, Martin Maechler, Ben Bolker, Steve Walker (2015). Fitting Linear Mixed-Effects
Models Using lme4. Journal of Statistical Software, 67(1), 1-48.
[19] Thomas KH, Martin RM, Potokar J, Pirmohamed M, Gunnell D. Reporting of drug induced
depression and fatal and non-fatal suicidal behaviour in the UK from 1998 to 2011. BMC Pharmacol
Toxicol. 2014 Sep 30;15:54.

17

medRxiv preprint doi: https://doi.org/10.1101/2020.04.10.20061358; this version posted April 14, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

Sato et al.

Figure legend
Figure 1. Forest plots, showing the aROR of each AE following the use of chloroquine (A) and
mefloquine (B). The number of reports of each AE, the reporting odds ratios that were adjusted based on
age and sex for each AE, and their 95% CI are provided in the adjacent tables. Note that the horizontal
axis of forest plots is provided in logarithmic scale. For AEs that were not reported after the use of
chloroquine or mefloquine (n = 0), the aROR was not calculated and appear as blank.

Abbreviations: AE, adverse event; aROR, adjusted reporting odds ratio; LOC, loss of consciousness;
AMS, altered mental status, N, number of observations; lower 95%, the lower limit of the 95%
confidence interval; upper 95%, the upper limit of the 95% confidence interval.

18

%

%

%

%

suicide
seizure
LOC
dizziness
amnesia
confusion
AMS
coma
stupor
somnolence
sedation
lethargy
delirium
disorientation
hallucination
delusion
psychosis
paranoia
anxiety
agitation
anger
aggression
nervousness
irritability
mood
behaviour
depression
restlessness
panic
nightmare

suicide
45 1.087 0.88 1.343
seizure
25 0.584 0.44 0.774
LOC
70 1.307 1.031 1.655 *
dizziness
178 0.991 0.872 1.127
amnesia
58 1.297 1.016 1.656 *
confusion
23 0.465 0.365 0.593
AMS
4 0.287 0.193 0.428
coma
3 0.178 0.057 0.554
stupor
0
somnolence
43 0.694 0.555 0.868
sedation
1 0.271 0.113 0.65
lethargy
10 0.538 0.363 0.796
delirium
17 1.575 1.06 2.341 *
disorientation
1 0.095 0.013 0.677
hallucination
24 2.117 1.536 2.918 *
delusion
4 1.509 0.717 3.174
psychosis
12 1.535 0.928 2.54
paranoia
0
anxiety
48 0.486 0.39 0.607
agitation
4 0.22 0.137 0.352
anger
2 0.533 0.281 1.011
aggression
7 0.939 0.555 1.588
nervousness
6 0.334 0.206 0.542
irritability
4 0.31 0.186 0.516
mood
2
behaviour
0
depression
117 1.469 1.218 1.772 *
restlessness
1 0.112 0.016 0.796
panic
10 0.775 0.456 1.315
nightmare
1 0.135 0.072 0.252
0.1

0.5 1.0 2.0 3.5

log( adjusted ROR )

6
0
2
5
5
0
0
0
0
0
0
0
1
0
1
1
4
4
15
2
0
3
0
0
0
4
13
0
6
5

%

6.437

4.853

8.538 *

4.596
3.336
10.925

2.961
2.539
6.281

7.134 *
4.384 *
19.002 *

5.6

3.015

10.401 *

%

5.051
2.95
8.648 *
14.469 3.089 67.767 *
16.235 9.407
28.02 *
63.311 21.602 185.548 *
29.866 21.625 41.248 *
5.238 2.895
9.476 *
10.956

5.344

22.462 *

25.708 9.025
15.178 11.047

73.23 *
20.854 *

40.987 21.261
33.612 16.67

79.016 *
67.774 *
1

2

3

4

5

log( adjusted ROR )

